Payment overview · 2025
General Payments
$381.15
13 reported records · 11 companies
Healthcare provider profile · identity verified
Craig V Broussard, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1609838861
Verified facts
What the public records show
CMS Open Payments records show Craig V Broussard, MD received $381.15 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 36.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.20 | 36.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.14 | 10.0% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $35.92 | 9.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.29 | 7.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $27.51 | 7.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.53 | 5.9% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $22.07 | 5.8% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $19.47 | 5.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.15 | 4.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.52 | 4.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.35 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.15 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.14 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $35.92 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $12.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $12.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 98 |
| Carvedilol | Carvedilol | 328 | 66 |
| Losartan Potassium | Losartan Potassium | 293 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 62 |
| Furosemide | Furosemide | 269 | 48 |
| Memantine Hcl | Memantine Hcl | 265 | 39 |
| Eliquis | Apixaban | 200 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 54 |
| Montelukast Sodium | Montelukast Sodium | 186 | 61 |
| Trazodone Hcl | Trazodone Hcl | 181 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 37 |
| Sertraline Hcl | Sertraline Hcl | 164 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 29 |
| Mirtazapine | Mirtazapine | 159 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 39 |
| Gabapentin | Gabapentin | 149 | 48 |
| Lisinopril | Lisinopril | 148 | 37 |
| Omeprazole | Omeprazole | 148 | 36 |
| Potassium Chloride | Potassium Chloride | 148 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 42 |
| Metformin Hcl | Metformin Hcl | 147 | 42 |
| Donepezil Hcl | Donepezil Hcl | 143 | 16 |
| Simvastatin | Simvastatin | 112 | 25 |
| Valsartan | Valsartan | 110 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 30 |
| Meloxicam | Meloxicam | 107 | 43 |
| Ezetimibe | Ezetimibe | 103 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 23 |
| Myrbetriq | Mirabegron | 97 | suppressed |
| Tradjenta | Linagliptin | 91 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 88 | 22 |
| Clonazepam | Clonazepam | 85 | 19 |
| Methylprednisolone | Methylprednisolone | 80 | 71 |
| Glimepiride | Glimepiride | 77 | 16 |
| Buspirone Hcl | Buspirone Hcl | 76 | 19 |
| Famotidine | Famotidine | 76 | 15 |
| Trulicity | Dulaglutide | 73 | 17 |
| Xarelto | Rivaroxaban | 72 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 71 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 22 |
| Azithromycin | Azithromycin | 66 | 61 |
| Metformin Hcl Er | Metformin Hcl | 66 | 24 |
| Farxiga | Dapagliflozin Propanediol | 62 | 13 |
| Synthroid | Levothyroxine Sodium | 62 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 14 |
| Tramadol Hcl | Tramadol Hcl | 62 | 26 |
| Bupropion Xl | Bupropion Hcl | 59 | suppressed |
| Alprazolam | Alprazolam | 57 | 24 |
| Diazepam | Diazepam | 53 | 15 |
| Irbesartan | Irbesartan | 53 | 17 |
| Jardiance | Empagliflozin | 52 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 13 |
| Allopurinol | Allopurinol | 46 | 15 |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 21 |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 29 |
| Rivastigmine | Rivastigmine | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Prednisone | Prednisone | 39 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 13 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Pentoxifylline | Pentoxifylline | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Mupirocin | Mupirocin | 25 | 16 |
| Risperidone | Risperidone | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 23 |
| Telmisartan | Telmisartan | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Risperidone Odt | Risperidone | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nisoldipine | Nisoldipine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Unithroid | Levothyroxine Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.15 · 13 records | Lilly USA, LLC | CHARTIS CATHETER, CREON, Cologuard Collection Kit, GIAPREZA, LEQVIO, LINZESS, MOUNJARO, OFEV, OTEZLA, PULMONX CHARTIS TABLET CONSOLE, REPATHA, UPTRAVI, Vest Therapy Und, YUPELRI, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error